A phase 3b, randomized, double blind, controlled study evaluating the efficacy and safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis subjects, homozygous for F508del mutation - VX18-445-109

StatusActive
Effective start/end date15/09/1930/11/20

Funding

  • Vertex